Oncotype DX - Is Your Patient Eligible?
The Oncotype DX Breast Recurrence Score test is a diagnostic test performed after a breast cancer surgery or biopsy, and provides information that’s important for treatment planning—such as an assessment of risk of distant recurrence1,3 and whether chemotherapy will be beneficial for your patient.2, 4
Eligibility
Patients are eligible for the Breast Recurrence Score test if they are:
- Recently diagnosed with invasive breast cancer
- Medically eligible for chemotherapy
And the cancer is:
- Anatomic stage I, II, or IIIa
- Estrogen-receptor positive (ER+)
- Human epidermal growth factor receptor-negative (HER2-)
NOTE: If your patient has been diagnosed with non-invasive breast cancer, ductal carcinoma in situ (DCIS) she may be eligible for the Oncotype DX Breast DCIS Score test.
The Breast Recurrence Score test can provide insight into specific diagnoses, treatment options, or risks factors, such as:
- Node-negative cancer
- Node-positive cancer
- Neoadjuvant treatments
- Locoregional recurrence risk
- Late recurrence risk
When to order the test
Because the goal of the Breast Recurrence Score test is to facilitate treatment planning, the best time to order the test is before treatment planning begins. Ordering is easy, and the test can be run on a post-surgery (lumpectomy or mastectomy) tumor sample or on a core biopsy.
Insurance and financial assistance
The Breast Recurrence Score test is covered by Medicare and most private insurers. In addition, Genomic Health created the Genomic Access Program (GAP) to help patients navigate the insurance and other payment options for Oncotype DX tests. Learn more about insurance coverage and financial assistance.